









Markets
/
Stocks
/
nasdaq-crbu
/

Caribou Biosciences Inc

CRBU

1.690USD

-0.090-5.06%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

157.38MMarket Cap

LossP/E TTM



Caribou Biosciences Inc

1.690

-0.090-5.06%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

147 / 506

Overall Ranking

256 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

8.857

Target Price

+397.59%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It is engaged in developing transformative therapies for patients with devastating diseases. Its genome-editing platform, including its Cas12a chRDNA technology, enables precision to develop cell therapies that are armored to potentially improve antitumor activity. Its pipeline includes three clinical-stage allogeneic cell therapies from its chimeric antigen receptor (CAR)-T (CAR-T) cell platform targeting the treatment of hematologic malignancies. CB-010 is the lead product candidate from its allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Its second product candidate, CB-011, is being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage phase I trial. CB-012 is its third product candidate.

Growing

The company is in a growing phase, with the latest annual income totaling USD 9.99M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 49.97.

Fairly Valued

The company’s latest PE is -0.95, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 57.50M shares, decreasing 37.92% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 4.09M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.40.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.19, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 2.67M, representing a year-over-year decrease of 23.01%, while its net profit experienced a year-over-year decrease of 43.51%.

Score

Industry at a Glance

Previous score

6.19

Change



Financials

5.94

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.12

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.65

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.97

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.24

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.00, which is -37.18% below the recent high of -0.63 and -1.69% above the recent low of -1.01.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 147/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.50, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Caribou Biosciences Inc is 5.00, with a high of 32.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Buy

Current Rating

8.857

Target Price

+397.59%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Caribou Biosciences Inc

CRBU

CRISPR Therapeutics AG

CRSP

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 5.74, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 2.05 and the support level at 1.61, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.74

Change

-0.14

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.036

Sell

RSI(14)

41.508

Neutral

STOCH(KDJ)(9,3,3)

12.528

Oversold

ATR(14)

0.110

Low Volatility

CCI(14)

-191.424

Sell

Williams %R

96.429

Oversold

TRIX(12,20)

-0.266

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.764

Sell

MA10

1.796

Sell

MA20

1.849

Sell

MA50

1.915

Sell

MA100

1.518

Buy

MA200

1.426

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 61.83%, representing a quarter-over-quarter decrease of 2.77%. The largest institutional shareholder is The Vanguard, holding a total of 4.09M shares, representing 4.39% of shares outstanding, with 12.89% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Pfizer Inc

4.69M

The Vanguard Group, Inc.

Star Investors

4.52M

-0.95%

Haurwitz (Rachel E. Ph.D.)

3.44M

-2.47%

Kynam Capital Management LP

3.27M

+35.87%

Two Sigma Investments, LP

2.49M

-3.90%

Schonfeld Strategic Advisors LLC

2.35M

+11.28%

ACATIS Investment Kapitalverwaltungsgesellschaft GmbH

2.00M

BlackRock Institutional Trust Company, N.A.

5.74M

-3.62%

Millennium Management LLC

821.05K

-4.51%

SELECTRA Management Company S.A.

1.51M

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.06, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 2.53. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.